Mark Neumann - 07 Aug 2023 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP, Chief Commercial Officer
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
07 Aug 2023
Net transactions value
-$2,223,060
Form type
4
Filing time
09 Aug 2023, 18:05:36 UTC
Previous filing
30 Mar 2023
Next filing
08 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $1,028,027 +55,300 +122% $18.59 100,639 07 Aug 2023 Direct
transaction ITCI Common Stock Sale $3,251,087 -55,300 -55% $58.79 45,339 07 Aug 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -55,300 -100% $0.000000* 0 07 Aug 2023 Common Stock 55,300 $18.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.3319 to $59.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 All shares underlying this option have vested.